SPACInsider•4 days ago
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
What is Okyo Pharma's quote symbol?
What is the 52 week high and low for Okyo Pharma (NASDAQ: OKYO)?
How much is Okyo Pharma's stock price per share?
What is Okyo Pharma's Market Cap?